Hybrid Biotherapeutics
Hybrid Biotherapeutics is dedicated to revolutionizing the treatment of solid tumor cancers through innovative cell therapy technology. Their mission is to transform resistant tumors into curable diseases by combining innate and adaptive immune system approaches, aiming to redefine cancer therapy and provide hope for treatment-resistant cases.
Industries
biotechnology
Nr. of Employees
small (1-50)
Products
Personalized dual-function cell therapy (preclinical, coming soon)
A planned personalized cell therapy that combines direct tumor‑killing activity with T‑cell priming and is designed to be manufactured via a non‑gene‑editing, GMP‑scalable process. Intended to pair with tumor-targeting antibodies (e.g., EGFR, HER2) to treat treatment‑resistant solid tumors.
Personalized dual-function cell therapy (preclinical, coming soon)
A planned personalized cell therapy that combines direct tumor‑killing activity with T‑cell priming and is designed to be manufactured via a non‑gene‑editing, GMP‑scalable process. Intended to pair with tumor-targeting antibodies (e.g., EGFR, HER2) to treat treatment‑resistant solid tumors.
Expertise Areas
- Personalized cell therapy for solid tumors
- Immuno-oncology
- Immune cell engineering without gene editing
- GMP cell therapy manufacturing
Key Technologies
- Cell-based immunotherapy
- Cell-mediated antibody delivery
- Non-gene-editing cell modification
- GMP manufacturing processes for cell therapies